NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-21-240 from the NIH Guide for Grants and Contracts. The goal of this funding opportunity is to support early phase clinical trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) for conditions that have been identified by NCCIH as high priority research topics. This funding opportunity is intended to support feasibility clinical trials, which will provide data that are critical for the planning and design of a subsequent controlled cohort study, clinical efficacy or effectiveness study, or a pragmatic trial. The data collected should be used to fill gaps in scientific knowledge necessary to develop a competitive full-scale clinical trial, including, but not limited to the following: examining feasibility and acceptability of interventions lacking published data; adapting an intervention to a specific population; refining the intervention to determine the most appropriate frequency or duration; determining feasibility of recruitment, retention and data collection procedures; refining and assessing the feasibility of protocolized multimodal interventions; or examining acceptability and adherence of control conditions. This FOA will not support randomized clinical trials to test or determine efficacy or effectiveness; nor will this FOA support repetition of feasibility or acceptability research that has been previously conducted in the same or similar patient population with the same or similar intervention. Applications that propose solely to write a protocol or manual of operations or to develop infrastructure for a clinical trial are not appropriate for this announcement. The subsequent larger trial should have the potential to make a significant impact on public health.
Notice NOT-DC-21-003 from the NIH Guide for Grants and Contracts
Notice NOT-DC-21-004 from the NIH Guide for Grants and Contracts
Notice NOT-HS-21-016 from the NIH Guide for Grants and Contracts
Notice NOT-MH-21-265 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AG-22-014 from the NIH Guide for Grants and Contracts. The goal of this Research and Entrepreneurial Development Immersion (REDI) Small Business Technology Transfer Research (STTR) Grant is to foster the career development of early career scientists with an interest in entrepreneurship by simultaneously supporting their entrepreneurial development and facilitating their transition to industry.
Funding Opportunity RFA-AG-22-007 from the NIH Guide for Grants and Contracts. The goal of this Research and Entrepreneurial Development Immersion (REDI) Small Business Innovation Research (SBIR) Grant is to foster thecareer development of early-career scientists with an interest in entrepreneurship by simultaneously supporting their entrepreneurial development and facilitating their transition to industry.
Funding Opportunity RFA-AG-22-004 from the NIH Guide for Grants and Contracts. The purpose of the NIA Research and Entrepreneurial Development Immersion (REDI): Mentored Entrepreneurial Career Development Award is to provide support and protected time (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence.
Funding Opportunity RFA-AG-22-003 from the NIH Guide for Grants and Contracts. The purpose of the Research and Entrepreneurial Development Immersion (REDI): NIA Entrepreneurship Enhancement Award (R25) is to promote the development of entrepreneurial training programs that are designed to broaden the skillset of graduate students and postdocs, as well as early career master's, Ph.D., and Dr.P.H. scientists, in fields relevant to the mission of NIA, including aging and Alzheimer's disease (AD) research. The goal of this program is to prepare trainees for a wide range of career paths, including those that are outside the normal research environment.
Funding Opportunity PAR-21-244 from the NIH Guide for Grants and Contracts. The purpose of the NIDA Animal Genetics Program is to identify genetic, genomic, and molecular (epi)genetic variants that underlie: 1. Phenotypes associated with addictive behaviors and/or vulnerability to distinct stages along the substance use disorder (SUD) trajectory (e.g. initial/acute use, escalation of use, acquisition of tolerance, dependence, uncontrolled use, abstinence and relapse or recovery); 2. Behaviors associated with SUD (e.g. impulsivity, novelty seeking, delayed discounting, and other genetically-associated phenotypes); and 3. Comorbidities that demonstrate genetic correlations with phenotypes and behaviors linked with SUD (e.g. anxiety, stress, poor maternal care, social defeat, and other paradigms). Applications may examine any type of variant, including single nucleotide variants (SNVs), indels, large and small structural variants, and all types of mobile DNA. NIDA encourages applications that take genomics, multi-omics, and/or data-based approaches that integrate multi-level omics data, delineate gene networks, and/or uncover the function of known or newly discovered genetic or epigenetic variants. NIDA expects these studies to uncover novel mechanisms that contribute to SUD and facilitate the discovery of targets for intervention and guide the development of individualized therapeutics to treat these different aspects of SUD.
Funding Opportunity RFA-AI-21-046 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to stimulate fundamental research of human disease-causing pathogens in the Bunyavirales order by supporting projects studying vector competence, virology, pathogenesis, and immunity.
Funding Opportunity RFA-AG-22-019 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will use the R01 funding mechanism to support discrete, specified, and circumscribed projects on novel molecular imaging approaches to establish high-resolution mapping of biomolecules in brain cells and regions during the course of aging and Alzheimers disease (AD).
Notice NOT-MH-21-305 from the NIH Guide for Grants and Contracts
Notice NOT-NS-21-074 from the NIH Guide for Grants and Contracts
Notice NOT-NS-21-075 from the NIH Guide for Grants and Contracts
Notice NOT-GM-21-052 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-RM-21-023 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the NIH Common Fund Bridge2AI Program which seeks to generate flagship data sets and best practices for the collection and preparation of AI/ML-ready data to address biomedical and behavioral research grand challenges. The purpose of this FOA is to support an integration, dissemination and evaluation center which will integrate activities across Bridge2AI Data Generation Projects to develop cross-cutting products and best-practices. This FOA invites cooperative agreement applications to develop a BRIDGE Center that will be responsible for integrating activities and knowledge across Data Generation Projects, disseminating products, best-practices, and skill development materials/activities, and evaluating all aspects of the Bridge2AI program with input from external stakeholder communities. The BRIDGE Center will combine cores of expertise in administration, team science, ethics, standards, tools optimization, and skills and workforce development.
Funding Opportunity RFA-NS-21-027 from the NIH Guide for Grants and Contracts. Reissue of RFA-NS-18-019: Understanding the dynamic activity of neural circuits is central to the NIH BRAIN Initiative. The invention, proof-of-concept investigation, and optimization of new technologies through iterative feedback from end users are key components of the BRAIN Initiative. This FOA seeks applications to optimize existing or emerging technologies through iterative testing with end users. The technologies and approaches should have potential to address major challenges associated with recording and modulation (including various modalities for stimulation/activation, inhibition and manipulation) of cells (i.e., neuronal and non-neuronal) and networks to enable transformative understanding of dynamic signaling in the central nervous system (CNS). These technologies and approaches should have previously demonstrated their transformative potential through initial proof-of-concept testing and are now ready for accelerated refinement. In conjunction, the manufacturing techniques should be scalable towards sustainable, broad dissemination and user-friendly incorporation into regular neuroscience research. Proposed technologies should be compatible with experiments in behaving animals, validated under in vivo experimental conditions, and capable of reducing major barriers to conducting neurobiological experiments and making new discoveries about the CNS. Technologies may engage diverse types of signaling beyond neuronal electrical activity such as optical, electrical, magnetic, acoustic or genetic recording/manipulation. Applications that seek to integrate multiple approaches are encouraged. If suitable, applications are expected to integrate appropriate domains of expertise, including biological, chemical and physical sciences, engineering, computational modeling and statistical analysis.
Funding Opportunity RFA-NS-21-026 from the NIH Guide for Grants and Contracts. Reissue of RFA-NS-18-020: Understanding the dynamic activity of brain circuits is central to the NIH BRAIN Initiative. This FOA seeks applications for proof-of-concept testing and development of new technologies and novel approaches for recording and modulation (including various modalities for stimulation/activation, inhibition and manipulation) of cells (i.e., neuronal and non-neuronal) and networks to enable transformative understanding of dynamic signaling in the central nervous system (CNS). This FOA seeks exceptionally creative approaches to address major challenges associated with recording and modulating CNS activity, at or near cellular resolution, at multiple spatial and/or temporal scales, in any region and throughout the entire depth of the brain. It is expected that the proposed research may be high-risk, but if successful, could profoundly change the course of neuroscience research. Proposed technologies should be compatible with experiments in behaving animals, validated under in vivo experimental conditions, and capable of reducing major barriers to conducting neurobiological experiments and making new discoveries about the CNS. Technologies may engage diverse types of signaling beyond neuronal electrical activity such as optical, magnetic, acoustic and/or genetic recording/manipulation. Applications that seek to integrate multiple approaches are encouraged. If suitable, applications are expected to integrate appropriate domains of expertise, including biological, chemical and physical sciences, engineering, computational modeling and statistical analysis.
Funding Opportunity RFA-NS-21-029 from the NIH Guide for Grants and Contracts. Reissue of RFA-NS-21-016: The goal of this funding opportunity announcement (FOA) is to solicit Initial Analgesic Development R61 applications that propose 2-year exploratory/planning awards that are expected to enable a future application for RFA-NS-21-015 HEAL Initiative: Team Research - for Initial Translational Efforts in Non-addictive Analgesic Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed). Thus, the limited scope of aims and approach of these applications are expected to establish a strong research team, feasibility, validity, or other technically qualifying results that support, enable, and/or lay the groundwork for a subsequent Team Research U19 application. These R61 awards will support the building of a research team to collect initial data and recruit additional collaborators. The proposal must include a plan for developing a strong research team, as well as a strategy to collect preliminary data linking putative therapeutic targets to the proposed pain indication and supporting the hypothesis that altering target activity will produce desirable outcomes for the disease.